Enhancement of the immunity to foot-and-mouth disease virus by DNA priming and protein boosting immunization

Vaccine

Volumn 19, Issue 28-29, 2001, Pages 4002-4010

  Shieh, Jeng Jer ^a   Liang, Chi Ming ^b   Chen, Chun Yi ^a   Lee, Fan ^c   Jong, Ming Hwa ^c   Lai, Shiow Suey ^d   Liang, Shu Mei ^a  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^b INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^c FISHERIES RESEARCH INSTITUTE   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

DNA vaccination; FMDV; Oligodeoxynucleotide

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; OLIGODEOXYNUCLEOTIDE; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL STRAIN BHK; CONJUGATE; CONTROLLED STUDY; FEMALE; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIREMIA; VIRUS INFECTION;

EID: 0035898920     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00114-1     Document Type: Article

References (48)

1. Foot and mouth disease virus
2. Control and prevention of foot-and-mouth disease in the Western hemisphere
3. New approaches to vaccination against foot-and-mouth disease
4. Protective immune response against foot-and-mouth disease
5. Natural adaptation to pigs of a Taiwanese isolate of foot-and-mouth disease virus
6. Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family: Aspects of virus protein synthesis, protein processing and structure
7. The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution
8. Antigenic variation of foot-and-mouth disease virus of serotype C during propagation in the field is mainly restricted to only one structural protein (VP1)
9. Location and characterization of the antigenic portion of the FMDV immunizing protein
10. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites
11. Structure of a major immunogenic site on foot-and-mouth disease virus
12. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents
13. The structure and antigenicity of a type C foot-and-mouth disease virus
14. Antibody recognition and neutralization of foot-and-mouth disease
15. Protective immune response to 16 kDa immunoreactive recombinant protein encoding the C-terminal VP1 portion of foot and mouth disease virus type Asia 1
16. Synthetic peptide vaccines: Foot-and-mouth disease virus as a model
17. Recombinant fusion protein and DNA vaccines against foot-and-mouth disease virus infection in guinea pig and swine
18. Isotype responses of infected, virus-vaccinated and peptide-vaccinated cattle to foot-and-mouth disease virus
19. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: Lack of solid protection in cattle and isolation of escape mutants
20. Need for cellular and humoral immune responses in bovines to ensure protection from foot-and-mouth disease virus (FMDV) - A point of view
21. Induction of Th1 and Th2, CD4+ T cell responses: The alternative approaches
22. DNA vaccines: Immunology, application and optimization
23. Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine
24. Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins
25. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
26. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
27. Enhancement of DNA vaccine potency using conventional aluminum adjuvants
28. Study of antigenic epitopes recognized by monoclonal antibodies of recombinant interferon-gamma
29. The strong positive correlation between effective affinity and infectivity neutralization of highly cross-reactive monoclonal antibody IIB4 which recognizes antigenic site B on influenza A virus haemagglutinin
30. Th1-cell and Th-2 cell-different patterns of lymphokine secretion lead to different functional properties
31. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization
32. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
33. Immature dendritic cells phagocytose apoptotic cells via αVβ5 and CD36, and cross-present antigens to cytotoxic lymphocytes
34. DNA vaccines: A key for inducing long-term cellular immunity
35. Efficient induction of an antigen-specific, T helper type 1 immune response by interleukin-12-secreting fibroblasts
36. CpG motifs in bacterial DNA trigger direct B-cell activation
37. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
38. Bacterial DNA induces murine intereferon-gamma production by stimulation of IL-12 and tumor necrosis factor-alpha
39. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
40. CpG islands as gene markers in the vertebrate nucleus
41. Contribution of CpG motifs to the immunogenicity of DNA vaccines
42. Gene vaccination: Plasmid DNA is more than just a blueprint
43. Oligonucleotide adjuvants for T helper 1 (Th1) specific vaccination
44. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants
45. CpG motifs as immune adjuvants
46. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines
47. Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination